You searched for "BJUI"

171 results found

Secondary bladder cancer following upper tract urothelial cancer

Upper tract urothelial carcinoma (UTUC) comprises <5% of all urothelial cancers. A certain proportion of patients with UTUC will develop secondary bladder urothelial cancer (BUC). This paper has retrospectively examined records obtained from several cancer USA population-based registries of more...

Intermittent vs. continuous hormonal therapy for metastatic prostate cancer

Continuous androgen deprivation therapy (cADT) is the standard management for metastatic prostate cancer (mPCa). Intermittent androgen deprivation therapy (iADT) is sought to have better quality of life (QoL) and adverse events profile during off-treatment period. This multicentre European randomised study...

PIRADS-3 lesions and clinically significant prostate cancer – what are we missing?

The use of pre-biopsy MRI has definitely enhanced our decision making in managing patients with suspected prostate cancer (PCa). There is still uncertainty around the outcomes for patients with PIRADS-3 lesions, with a small but definite risk of missing clinically...

Prostate biopsies without antibiotic cover – are we there yet?

Transperineal (TP) prostate biopsies are widely replacing the traditional transrectal route due to definite evidence of reduced infective complications. TP biopsies are usually performed with a single dose of antibiotic pre-procedure in most centres. In this article the authors attempt...

BCG after TURBT – does timing matter?

Intravesical bacille Calmette–Guerin (BCG) therapy continues to be widely used for patients with intermediate / high-risk non-muscle invasive bladder cancer (NMIBC). In this article, the researchers identified the lack of sufficient evidence with regards to timing of BCG after transurethral...

Loop-tail stents in reducing stent related symptoms – the search continues

Insertion of double J (DJ) stents is one of the most commonly performed procedures in urology. One of its major drawbacks is stent related symptoms (SRS) which has generated a lot of research in drugs, stent design and materials. One...

Testosterone supplementation after prostatectomy – journey from bad to good

The role of androgens in the pathogenesis of prostate cancer is quite complex and is not entirely clear yet. Despite several reports suggesting testosterone use is safe in patients diagnosed with prostate cancer, many clinicians are still reluctant to use...

Changing concepts in endourological training – SIMULATE trial

Skill acquisition for endourological procedures is markedly different from traditional open surgical procedures, questioning the applicability of the presently used apprenticeship model. The lack of a universal simulation training curriculum has hampered its adoption into mainstream urological training. This study...

Supranormal function on MAG-3 – what is its significance and how to predict?

Differential renal function (DRF) on MAG-3 scans is typically used in patients with pelvic ureteric junction obstruction (PUJ obstruction). Supranormal DRF is when the kidney with PUJO has higher DRF than the normal contralateral kidney. The authors in this study...

Do stones still kill?

This paper is a retrospective analysis of deaths ascribed to stone disease in England and Wales over a 15-year period. The data was obtained from the Office of National Statistics, based on mortality derived from death certificates. One thousand, nine...

Reducing the burden of NMIBC: outpatient laser management in morbid patients

With non-muscle invasive bladder cancer (NMIBC) posing a significant burden on urological departments, alternative ways of safely and effectively managing these patients with a minimally invasive approach is desirable. As rates of recurrence are high but progression rates low, and...

Comparative effectiveness of nephron sparing surgery vs ablation

Nephron sparing surgery (NSS) and minimally invasive modality of thermal ablation have attracted great attention as an alternative surgical treatment to radical nephrectomy (RN) for renal tumours <4cm. High quality evidence comparing disease specific survival (DSS) is lacking. This issue...